Compare Nucor Corporation (NUE) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs 10X Genomics Inc — how do they compare? Nucor Corporation trades at $250.33 (market cap $55.84B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Nucor Corporation is far larger — about 5.5× 10X Genomics Inc's market cap, and Nucor Corporation pays a 0.91% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and 10X Genomics Inc for 91 Days on average.
| NUE | TXG | |
|---|---|---|
Market Cap | $55.84B | $10.07B |
Volume | 848,835 | 5,657,286 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $97.74 |
52-Week Low | $131.78 | $11.48 |
Typical Hold Time | 78 Days | 91 Days |
Enterprise Value | $60.25B | $9.59B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.14, down 0.12% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The company reported strong Q2 2026 EPS of $4.84, beating expectations, and issued Q3 2026 guidance anticipating higher earnings. Revenue is projected to grow to $36.1B in 2026, with net income margin improving to 7.98%. Analyst consensus is a 'Moderate Buy' with a $266.88 price target, suggesting potential upside from current levels.
The outlook for NUE is cautiously optimistic, supported by earnings momentum and steel price strength, but tempered by competitive pressures and cyclical industry risks. Investment opportunity lies in execution of growth initiatives and dividend consistency, while key risks include economic sensitivity and new capacity additions in the steel sector impacting pricing power.
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
